The decision to prescribe a compounded or brand-name glucagon-like peptide 1 (GLP-1) medication for obesity treatment was never simple, but recent developments have complicated it further.

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

Now, though, on platforms like Instagram and Facebook, ads for oral knock-off versions of GLP-1 drugs are proliferating. After the brand-name GLP-1 drugs went into shortage in 2022, a booming ...

Investigators presented the latest research on the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs ... based on brand names approved by the [Food and Drug Administration] for type ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

"FDA clears Veru’s IND for GLP-1 RA-associated muscle loss drug" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has ...

In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite. (HealthDay News) — For patients with ischemic stroke, sodium-glucose ...

Significant reduction seen in VTE rates, with similar reductions for patients with and without obesity. (HealthDay News) — For patients with type 2 diabetes mellitus (T2DM), glucagon-like ...

and liraglutide (sold under the brand names Saxenda and Victoza) are glucagon-like peptide-1 receptor agonists, or GLP-1 RA medications. Those FDA-approved medications help lower blood sugar ...

The incoming Trump administration would need to sign off on the new legislation. (HealthDay News) — The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide ...